Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT06006598
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06004947
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05994547
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
Remimazolam for Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 120
- Registration Number
- NCT05980117
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine, Los Angeles, California, United States
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT05952089
- Locations
- 🇺🇸
Research Integrity LLC, Owensboro, Kentucky, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Sinai Hospital Of Baltimore, Baltimore, Maryland, United States
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 20
- Registration Number
- NCT05947604
- Locations
- 🇲🇾
Clinical Research Center (CRC) Ampang Hospital, Kuala Lumpur, Malaysia
Ketamine and Midazolam Infusions for CRPS: Feasibility Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Stanford University
- Registration Number
- NCT05945147
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT05932277
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
Clinical Study of Oral Midazolam Combined With Esketamine Administered Intranasally for Pediatric Preoperative Sedation
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-06-29
- Target Recruit Count
- 126
- Registration Number
- NCT05925283
- Locations
- 🇨🇳
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.